Skip to main content
Back

2026 Global healthcare equities outlook: Innovation supports healthcare’s long‑term case

24 March 2026

Steven Slaughter, Lead Portfolio Manager

CJ Sylvester, Portfolio Manager

In 2025, global healthcare equities once again demonstrated their lower volatility profile. Early in the year, global equities experienced a meaningful correction as artificial intelligence (AI)-related stocks sold off and higher-than-expected US tariffs fuelled uncertainty among investors. During this period, healthcare equities proved more resilient, recording a noticeably smaller drawdown than the broader market. Although the sector trailed the rebound of global equities - despite both finishing in positive territory for the full year - we believe that the defensive characteristics of the overall healthcare industry, coupled with remarkable therapeutic innovations in the biopharmaceutical, MedTech, and tools sub-segments of this sector, will continue to be rewarded with capital appreciation over a full market cycle. Current valuations relative to the broader market make for an attractive entry point today, and periods like this tend to lead to outperformance for healthcare stocks over the long term.

Summary:

  • Regulatory and public policy changes were significant overhangs for healthcare in 2025. However, we believe that the passage of time has allowed greater visibility on several mitigating factors.
  • Within the biopharmaceuticals, MedTech and life science tools, and healthcare providers and services industries, we see abundant investment opportunities in 2026.
  • Demographic trends in healthcare, coupled with remarkable therapeutic innovations of this sector, will likely continue to be rewarded with share-price gains over a full market cycle.

 

Download full PDF

  • 2026 Mid-year outlook: Asian Fixed Income

    In this Mid-Year Outlook, the Asian Fixed Income team explains this important change in monetary policy expectations, and why the asset class is well positioned to capitalise on it.

    Read more
  • 2026 Mid-year outlook: Greater China Equities

    Greater China equity markets showed divergent trends in the first half of 2026, with China A-shares and the Taiwan Taiex index registering strong gains driven by resilient technology exports amid global demand for artificial intelligence (AI). Meanwhile, the MSCI China market pulled back, weighed by commerce subsidies amid fierce competition in food delivery and rising AI capital expenditure, which we believe have already been priced in. In this mid-year Outlook, we highlight five positive drivers for China and Hong Kong equities in the second half of the year. Furthermore, the team explains why it believes the Taiwan region’s technology sector should continue to enjoy positive momentum.

    Read more
  • 2026 Mid-Year Outlook Series: Asia Equities ex-Japan

    Asia equities ex-Japan continued the significant momentum from 2025 with strong performance throughout the first half of the year. Amid numerous catalysts, June Chua, Head of Asia Equities outlines in this Mid-Year Outlook why she is constructive on the asset class for the remainder of 2026. Positive drivers include: potential geopolitical resolution in the Middle East and lower energy costs, supportive earnings and valuations, and differentiated growth drivers across the region.

    Read more
See all
  • 2026 Mid-year outlook: Asian Fixed Income

    In this Mid-Year Outlook, the Asian Fixed Income team explains this important change in monetary policy expectations, and why the asset class is well positioned to capitalise on it.

    Read more
  • 2026 Mid-year outlook: Greater China Equities

    Greater China equity markets showed divergent trends in the first half of 2026, with China A-shares and the Taiwan Taiex index registering strong gains driven by resilient technology exports amid global demand for artificial intelligence (AI). Meanwhile, the MSCI China market pulled back, weighed by commerce subsidies amid fierce competition in food delivery and rising AI capital expenditure, which we believe have already been priced in. In this mid-year Outlook, we highlight five positive drivers for China and Hong Kong equities in the second half of the year. Furthermore, the team explains why it believes the Taiwan region’s technology sector should continue to enjoy positive momentum.

    Read more
  • 2026 Mid-Year Outlook Series: Asia Equities ex-Japan

    Asia equities ex-Japan continued the significant momentum from 2025 with strong performance throughout the first half of the year. Amid numerous catalysts, June Chua, Head of Asia Equities outlines in this Mid-Year Outlook why she is constructive on the asset class for the remainder of 2026. Positive drivers include: potential geopolitical resolution in the Middle East and lower energy costs, supportive earnings and valuations, and differentiated growth drivers across the region.

    Read more
See all
Important notice

With effect from 2 July 2026, the Customer Service Centre of Manulife Investment Management (Hong Kong) Limited is relocated to 23/F., Manulife Tower, One Bay East, 83 Hoi Bun Road, Kwun Tong, Kowloon.  This centre provides customer services in relation to Manulife InvestChoice Accounts, Manulife Advanced Fund SFC, Manulife Global Fund and Manulife Hong Kong Series.  Please call Customer Contact Centre at 2108 1110 to make an appointment prior to your visit.  

View more